A pooled analysis of tirzepatide, currently the only GIP/GLP-1 receptor agonist, in 4036 participants regardless of diabetes status, for a treatment duration of 12 to 72 weeks, showed a significant weight loss of mean difference of −7.7 kg (−8.1%), −11.6 kg (−11.9%), and −11.8 kg (−12.4%) compared to placebo for doses of 5, 10, and 15 mg, respectively. Here, GIP is linked to diabetes mellitus.